Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial-Reference-Cited by-同舟云学术

Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

Published:2020-10-30 Issue:6 Volume:14 Page:985-996
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Li Xiaoke,Zhou Daqiao,Chi Xiaoling,Li Qin,Wang Li,Lu Bingjiu,Mao Dewen,Wu Qikai,Wang Xianbo,Zhang Mingxiang,Xue Jingdong,Li Yong,Lu Wei,Guo Jianchun,Jiang Feng,Zhang Xinwei,Li Zhiguo,Yang Xianzhao,Guo Hui,Gan Danan,He Liyun,Luo Lin,Zhang Ludan,Du Hongbo,Ye Yong’an^ORCID

Funder

China National Science and Technology major projects 12th 5-year plan

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-020-10097-z.pdf

Reference43 articles.

1. Aparna S, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546–55.

2. Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

3. Xiaofeng L, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009;200(1):39–47.